Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 9/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 8/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.39 |
| ▸ | BDKRB1 | P46663 | 3/20 | 0.38 |
| ▸ | KRAS | P01116 | 1/20 | 0.36 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.35 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.35 |
| ▸ | HPGDS | O60760 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19105598 | 0.83 | HPGDS (0.41) | HPGDS | |
| SCHEMBL19117337 | 0.83 | MAPK14 (0.39) | S1PR3S1PR1S1PR2HPGDSCYP2C9 | |
| SCHEMBL19105572 | 0.79 | HPGDS (0.42) | HPGDSMAPK14 | |
| SCHEMBL25138292 | 0.75 | HDAC6 (0.50) | — | |
| SCHEMBL19698928 | 0.70 | HCAR2 (0.43) | — | |
| SCHEMBL22924509 | 0.70 | HPGDS (0.49) | S1PR3S1PR1S1PR2HPGDS | |
| SCHEMBL19698929 | 0.69 | EGLN1 (0.43) | HPGDS | |
| SCHEMBL30445348 | 0.69 | HPGDS (0.39) | HPGDS | |
| SCHEMBL19698958 | 0.68 | GCG (0.43) | — | |
| SCHEMBL13465582 | 0.67 | LMNA (0.42) | HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210188860-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | Grünenthal GmbH (DE) | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188860-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, OPRL1 | S1PR3 1557/4885S1PR1 1891/4885S1PR2 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.